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Prescription medicines: decision-making preferences of patients who
receive different levels of public subsidy
Abstract
Objective To compare the relative importance of medicine attributes and decision-making preferences of
patients with higher or lower levels of insurance coverage in a publicly funded health care system. Design and
setting Cross-sectional telephone survey of randomly selected regular medicine users aged ≥18 years in the
Hunter Valley, NSW, Australia. Main variables studied Questions about 27 medicine attributes and active
involvement in decisions to start a new medicine. Results After adjustment, there were few differences
between the 408 concession card holders (high insurance) and 410 general beneficiaries (low insurance) in
their assessment of the importance of medicine attributes. For both groups, the explanation of treatment
options, establishing the need for the medicine, and medicine efficacy and safety were the most important
considerations. Medicine costs, the treatment burden and medicine familiarity were less important; the views
of family and friends ranked lowest. There was a statistically significantly greater influence of the regular
doctor for the concession card holders than general beneficiaries (93.6 vs. 84%, adjusted OR 2.80, 95% CI
1.31, 5.99). Concession card holders were more likely to favour doctors having more say in the decision-
making process (crude OR 1.69, 95% CI 1.28, 2.24), and more likely to report the most recent treatment
decision being made by the doctor alone, compared with general beneficiaries (61.2 vs. 40.3%). Conclusion
Medicine need, efficacy and safety are viewed as paramount for most patients, irrespective of insurance status.
While patients report the importance of participation in treatment decisions, delegation of decision making to
the doctor was common in practice.
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Abstract
Objective To compare the relative importance of medicine attri-
butes and decision-making preferences of patients with higher or
lower levels of insurance coverage in a publicly funded health care
system.
Design and setting Cross-sectional telephone survey of randomly
selected regular medicine users aged ‡18 years in the Hunter Valley,
NSW, Australia.
Main variables studied Questions about 27 medicine attributes and
active involvement in decisions to start a new medicine.
Results After adjustment, there were few differences between the
408 concession card holders (high insurance) and 410 general
beneficiaries (low insurance) in their assessment of the importance of
medicine attributes. For both groups, the explanation of treatment
options, establishing the need for the medicine, and medicine efficacy
and safety were the most important considerations. Medicine costs,
the treatment burden and medicine familiarity were less important;
the views of family and friends ranked lowest. There was a
statistically significantly greater influence of the regular doctor for
the concession card holders than general beneficiaries (93.6 vs. 84%,
adjusted OR 2.80, 95% CI 1.31, 5.99). Concession card holders were
more likely to favour doctors having more say in the decision-
making process (crude OR 1.69, 95% CI 1.28, 2.24), and more likely
to report the most recent treatment decision being made by the
doctor alone, compared with general beneficiaries (61.2 vs. 40.3%).
Conclusion Medicine need, efficacy and safety are viewed as para-
mount for most patients, irrespective of insurance status. While
patients report the importance of participation in treatment decisions,
delegation of decision making to the doctor was common in practice.
doi: 10.1111/j.1369-7625.2011.00715.x
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Background
Most high-income countries and a growing
number of low- and middle-income countries
provide drug benefits programmes that protect
patients from prohibitive medicine costs.1 Often
that protection comes in the form of a publicly
funded price subsidy to the patient. These pro-
grammes have been under increasing financial
pressures in recent years because of the high
costs of new drugs. Governments have a limited
range of responses to this budgetary pressure.
They can achieve lower prices through tendering
and generic substitution, can use pharmaco-
economic analyses to demonstrate value and
sometimes argue for lower prices, or they can
share some of the costs with patients by requir-
ing co-payments.1
There is considerable variation in how gov-
ernments share the costs of medicines with
consumers. Some cover a proportion of the total
medicine costs; others use a fixed co-payment,
possibly linked to a measure of ability to pay.1
In Australia, where this study was conducted,
patients pay a fixed amount, but the amount
depends on their welfare status. There is a safety
net that reduces medicine costs beyond a certain
annual level of consumption; despite this, co-
payment costs can still cause hardship and
impact adversely on the individuals capacity to
afford medications.2–4 In Australia, there is evi-
dence that costs impact differently on prescrip-
tion medicine use by general beneficiaries and
concession card holders.2,5
Most research in this field has addressed the
affordability of medicines covered by insurance
programmes. But at its core, the policy of
charging patients is not simply about sharing
costs. There is a common but largely unstated
view that strong price signals to patients may
influence attitudes and behaviours and reduce
wasteful practices. The concern is that overly
generous benefits carry risks – a moral hazard.
So, investigation of the behaviours of patients
and their responses to cost sharing requires an
analysis of beliefs and attitudes towards the
provision of medicines and an investigation of
whether these differ between individuals with
higher or lower levels of insurance coverage.
These beliefs and attitudes are likely to be
influenced by how patients view their relation-
ships with their doctors, who are important
agents in the chain of events that result in the
writing of a subsidised prescription.
The work described here is part of a larger
study exploring the impact of cost sharing by
patients in Australia on medicine choices and
utilisation. This study asked respondents to
quantify the relative importance of a number of
medicine attributes and the extent to which they
delegate responsibility for decision making to
their doctor. We contrasted responses from
general beneficiaries and concession card holders
to assess the influence of the different levels of
insurance coverage. We compared patients
preferred (stated) decision-making role with
their self-reported role (revealed decision mak-
ing) in a recent decision to start a new medicine.
Finally, we determined patients satisfaction
with the information communicated to them on
the efficacy, safety and cost of the new medicine.
The results of this study will be used in a discrete
choice experiment,6 to measure their prepared-
ness to trade-off the clinical benefits, side effects
and cost of alternative medicines.
Methods
This cross-sectional survey of regular medicine
users was conducted between April and June
2008 in the Hunter Valley region of New South
Wales, Australia. The study was approved by
the University of Newcastle Human Research
Ethics Committee.
Participants
Participants had to be current users of prescrip-
tion medicines who anticipated using them for
the next 6 months. Respondents were categor-
ised according to their eligibility for concessional
benefits under the Australian Pharmaceutical
Benefits Scheme.7 In 2011, general beneficiaries
(who do not receive welfare payments) pay a
maximum of AU$ 34.20 per prescription item,
while concession card holders (elderly and those
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in receipt of social security support) pay up to
AU$ 5.60 per prescription item. A safety net
scheme protects people with high medication
needs. Once an individual or family reaches a
safety net threshold (AU$ 1317.20 for general
beneficiaries and AU$ 336.00 for concession card
holders), the medicine will be less expensive
(AU$ 5.60 for general beneficiaries) or free (for
concession card holders) for the rest of the cal-
endar year. There is optional private health
insurance in Australia but this does not routinely
cover the costs of prescription medicines. Infor-
mation was obtained on participants age, gen-
der, highest level of education completed,
marital and employment status, number of chil-
dren in the household, and whether or not they
had a regular doctor or held private health
insurance. In addition, we collected informa-
tion on self-reported health status using five




We used the results from qualitative work pre-
viously conducted by us2 and from themes iden-
tified from the literature8–11 to identify key
attributes of medicines that might influence par-
ticipants decisions about starting a new medi-
cine. We developed 26 questions related to the
nine attributes as follows: – benefits associated
with the medicine (three items), risks of the
medicine (three items), the need for the medicine
(three items), cost (three items), other treatment
options (three items), who recommended the
treatment (three items), the burden or inconve-
nience associated with taking the medicine (four
items), previous experience with the medicine
(one item) and the importance of the views
of others including family and friends (three
items). As we wanted to examine roles in decision
making, we added a single question asking
respondents about the importance of being
actively involved in the decision to start a new
medicine.
In total, there were 27 items assessing the
importance of the medicine attributes. These
were scored using a five-item Likert response
scale (not at all important, of little importance,
moderately important, important and very
important). Question sets were grouped (e.g.
those relating to benefits or side effects) and
presented to respondents in randomised order,
and symmetrical scales were randomly presented
in proper or inverted order; both of these tech-
niques reduce the bias from order effects.12
Decision making-role
In addition to the single item in the medicines
attributes part of the survey, we explored the
preferred (stated) decision-making role for par-
ticipants using the validated Degner Control
Preferences Scale.13 Respondents were asked to
imagine they had to make an important choice
about treatment for themselves (an example
might be deciding whether to take a cholesterol-
lowering medicine or a blood pressure medicine).
Each participant was asked a series of questions,
comparing two options at a time; the options
provided are categorised into five preferred
decision-making roles with increasing delegation
of authority for decision making to the doctor.
The categories are as follows: (i) making the
decision yourself, (ii) you make the decision
yourself after seriously considering the doctors
opinion, (iii) you and the doctor share equally
in deciding about your treatment, (iv) doctor
makes the final decision after seriously consid-
ering your opinion and (v) you would prefer to
leave all decisions regarding treatment to your
doctor.
To compare respondents stated preference for
decision making with recall of their actual
(revealed) decision-making role, we asked who
had made the decision the last time a new
medicine had been started. Response options
were as follows: the doctor decided for you, you
and your doctor decided together, you decided
by yourself or you can not remember.
Satisfaction with information provided
We asked participants how much information
was provided by the doctor on the potential
benefits, side effects and costs of the last new
medicine started. Response options for each
Prescription medicines: decision making preferences of patients, J Robertson et al.
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aspect were as follows: you received no infor-
mation, you wanted more information, you
received as much information as you wanted and
you received more information than you
wanted.
Procedure
A three-phase pilot test of the survey consisted of
50 completed interviews, with participants drawn
from Hunter Valley households not included in
the study. At the end of each phase of testing,
minor modifications were made to further refine
the wording and flow of the questionnaire. A
copy of the survey is available on request. The
final survey instrument was administered using a
computer-assisted telephone interview (CATI)
system by trained staff at the not-for-profit
Hunter Valley Research Foundation (http://
www.hvrf.com.au/). The procedures standar-
dised the introduction scripts, wording of all
questions and response options and directed the
interview using skips, branching questions and
prompts as appropriate. Randomisation was
applied to both household selection (random
digit dialling of households from the NSW
ElectronicWhite Pages) and participant selection
to minimise bias and reduce volunteer effects.
Up to 10 attempts were made to contact the
household. The person answering the telephone
was asked the number of people in the household
aged ‡18 years and his ⁄her age position in
the household. The CATI system selected one
person at random e.g. Nth oldest, with no
substitutions permitted. This sequence prevented
the person answering the telephone misrepre-
senting themselves as the selected respondent.
Eligible participants were regular medicine users.
The purpose of the study was explained, and
verbal consent to continue with the interview
was obtained. The interview could be resched-
uled to a more convenient time and, where
requested, additional written information sent to
the selected respondent before the interview
proceeded. Quota sampling was used to ensure
that there were equal numbers of general bene-
ficiaries and concession card holders included
in the survey. Interviewers for the study under-
went training in the background to the study,
detailed CATI collection procedures and
methods and up to 2 h practical experience in the
conduct of the survey and addressing potential
respondent questions. Data were recorded in two
separate databases: one with the results of every
completed interview in the study and the second
recording every call attempt.
Principal component analysis
To check that the attributes of medicines pro-
posed by us identified the key components that
might influence decision making, responses to
the 27 Likert scale items were subjected to a
principal component analysis (PCA). PCA is a
variable reduction procedure resulting in a small
number of components that account for most of
the variance in a set of observed variables (sur-
vey items). The principal axis method was used
to extract the components. The mathematical
method looks for a linear combination of vari-
ables that extracts the maximum variance.14 It
then removes this variance and seeks a second
linear combination that explains the maximum
proportion of the remaining variance. This is
repeated, resulting in a series of orthogonal
(uncorrelated) factors or components. Both the
eigenvalue greater than one criterion (Kaiser
criterion) and the scree test were used to deter-
mine the number of components extracted.14
Factors with low eigenvalues (<1) contribute
little to the explanation of variances and are
ignored in favour of more important factors.
The scree test is a graphical representation of
eigenvalues; the elbow of the curve indicating a
possible solution for the number of components.
The components were then subjected to a Vari-
max rotation, an orthogonal rotation of the
factor axes that facilitates identification of each
variable with a single component. In interpreting
the rotated component pattern, an item was said
to load on a given component if the factor
loading was 0.4 or greater for that component
and was <0.4 for other components.
To check the validity of the PCA approach we
applied, we re-examined the component solution
by randomly dividing the responses from the
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participants into two groups, using one half of
the responses to develop the components (fac-
tors) and the remaining responses to confirm
that the components identified adequately rep-
resented the data collected.
Statistical analysis
Descriptive statistics were used to summarise the
data. Likert scale responses for the 27 items
assessing the importance of medicine attributes
were divided into two categories – important
(important and very important) and not so
important (moderately important, of little
importance and not at all important). Logistic
regression analyses were conducted to examine
differences between the concession card holder
and general beneficiary groups in demographic
characteristics and responses to the 27 questions,
with patient category as the outcome variable.
We derived crude and adjusted odds ratios and
95% confidence intervals, adjusting for age, sex,
education, employment status, marital status,
private health insurance status, regular GP, self-
reported health and number of children in the
household. Ordinal linear regression analysis
was used to examine the differences between
concession card holders and general beneficiaries
in responses on the Degner Control Preferences
Scale, self-reported participation in the most
recent decision to start a medicine and satisfac-
tion with the information provided on benefits,
side effects and costs of that medicine. We
derived crude and adjusted odds ratios and 95%
confidence intervals, adjusting for the demo-
graphic characteristics listed earlier. All analyses
were performed with SAS 9.2 (SAS Institute,
Cary, NC, USA).
Results
Overall, the CATI interviews took an average of
21 min to complete. Of 1222 eligible household
contacts, there were 388 household and personal
refusals, 16 incomplete and 818 completed
interviews (408 concession card holders, 410
general beneficiaries), giving a response rate of
67%.
As expected, there were statistically significant
differences between concession card holders and
general beneficiaries on all variables measured
except gender (Table 1). Concession card hold-
ers were older, had lower levels of education, a
lower proportion were employed, fewer were
married, they had lower rates of private health
insurance and reported slightly worse overall
health. Concession card holders had fewer chil-
dren aged less than 18 years in the household
and more had a regular GP than did respon-
dents in the general beneficiary category.
While our sample contained fewer men than
the Australian population (37 vs. 49.4%,
respectively), reported rates of private health
insurance coverage were similar to the Austra-
lian population at that time.15
Principal component analysis
The principal component analysis was con-
ducted on usable responses from 709 partici-
pants. Only the first eight components displayed
eigenvalues >1, and the results of the scree test
also suggested that only the first eight compo-
nents were meaningful, and these were retained
for rotation. Combined, these eight components
accounted for 57% of the total variance in
participants responses. The eight components
identified were labelled decision making, the need
for the medicine, benefits, risks, trust (the doctor
involved), cost, the burden associated with
treatment, familiarity with the medicine. Testing
of the PCA procedure using two random sam-
ples of responses confirmed the eight-component
solution.
Importance of attributes
The importance of each of the 27 aspects on
the decision to start a new medicine is sum-
marised in Table 2, with the responses grouped
according to the categorisation determined by
the principal components analysis. Responses
to the survey questions were not normally
distributed; 15 attributes were identified as
important or very important by more than 80%
of respondents.
Prescription medicines: decision making preferences of patients, J Robertson et al.
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Concession card holders versus general
beneficiaries
There were small but statistically significant
differences between concession card holders and
general beneficiaries in the assessment of the
importance of eight of the 27 items. However,
after adjustment for demographic characteris-
tics, a statistically significant difference remained
for only one item, How important is it that your
regular doctor has prescribed it?, ranked impor-
tant or very important by more concession card
holders than general beneficiaries (93.6 vs. 84%,
adjusted odds ratio 2.80, 95% CI 1.31, 5.99,
Table 2).
Ranking of items
Highest ranked in importance for the respon-
dents was the explanation of all treatment
options available; knowing that there might be
non-medicine alternatives, such as diet or exer-
cise, and having time to consider the options
presented were ranked lower (ranks 15 and 17,
respectively).
After the explanation of all treatment options,
information on the need for the medicine was
important to participants (ranks 2, 4, 5, 14). The
doctors assessment of need was rated more
important than the respondents own perceived
need for treatment (rank 5 vs. 14).









Mean age in years (SE) 65.4 (0.72) 49.3 (0.65) 1.09 (1.07, 1.10)
Gender (%)
Male 38.2 36.3 1.00
Female 61.8 63.7 0.92 (0.69, 1.22)
Highest level of education (%)
Primary 4.7 1.2 16.3 (5.5, 47.7)
Lower secondary 53.2 28.0 8.1 (4.9, 13.2)
Technical college 26.7 32.4 3.5 (2.1, 5.8)
Higher School 9.3 12.2 3.3 (1.7, 6.0)
Certificate ⁄ College University 6.1 26.1 1.00
Employment status (%)
Employed 10.8 75.3 1.00
Not employed 89.2 24.7 25.2 (17.1, 37.0)
Marital status (%)
Married 45.6 66.6 1.00
Not married 54.4 33.4 2.4 (1.8, 3.2)
Private health insurance (%)
Yes 44.6 71.7 0.32 (0.24, 0.43)
No 54.9 28.0 1.00
Has a regular GP (%)
Yes 98.3 92.9 4.4 (1.9, 10.1)
No 1.7 7.1 1.00
Self-reported overall health (%)
Poor 8.1 2.7 1.00
Fair 25.0 13.2 0.63 (0.30, 1.34)
Good 38.7 41.5 0.31 (0.15, 0.63)
Very good 24.0 32.2 0.25 (0.12, 0.51)
Excellent 3.9 10.5 0.12 (0.05, 0.30)
Number of children in household (%)
None 88.7 65.9 1.00
One 5.4 14.6 0.27 (0.16, 0.46)
Two 3.7 13.2 0.21 (0.11, 0.38)
Three or more 2.2 6.3 0.26 (0.12, 0.56)
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Aligned with need was whether the medicine
will work (rank 3). Whether the medicine would
offer a cure or provide symptom relief seemed to
be of slightly lower importance (rank 9) as was
how long it will take for the medicine to work
(rank 16).
After need and benefits of treatment, side
effects were important to participants, both the
short-term and long-term side effects that might
be associated with the medicine (ranks 6 and 8)
rather than the more specific assessment of their
personal risk of side effects (rank 11). However,
these differences in ranking are minor, with
more than 87% of participants rating informa-
tion on all three questions around side effects as
important or very important.
That it was your regular doctor (rank 10) or a
specialist (rank 12) who prescribed the drug was
Table 2 Importance of attributes of medicines
How important are the following aspects in helping you decide










That all treatment options have been explained to you 1 97.5 98.8 0.49 (0.17, 1.45)
That you are directly involved in decision about medicine 7 90.6 90.9 0.97 (0.60, 1.55)
That there are non-medicine alternatives (diet ⁄ exercise) 15 80.3 86.0 0.66 (0.46, 0.96)
Having time to think about options before commencing 17 78.6 80.4 0.89 (0.63, 1.25)
Need
That the medicine will protect you from getting worse 2 97.8 97.8 0.99 (0.39, 2.53)
What might happen if you do not treat the condition 4 96.3 96.3 1.00 (0.48, 2.07)
That the doctor says you need the medicine 5 95.3 92.2 1.73 (0.97, 3.11)
That you think you need the medicine 14 85.7 83.0 1.23 (0.84, 1.80)
Benefits
How effective the medicine is likely to be 3 96.8 97.8 0.68 (0.29, 1.61)
That the medicine will cure rather than symptom relief 9 90.7 88.5 1.27 (0.81, 2.01)
Risks
The possible long term side effects of the medicine 6 91.1 94.6 0.58 (0.33, 1.00)
The side effects associated with the medicine 8 90.6 89.7 1.11 (0.70, 1.76)
The personal risks of side effects 11 87.2 88.0 0.93 (0.61, 1.41)
Trust
That your regular doctor has prescribed it* 10 93.6 84.0 2.77 (1.72, 4.47)
That a specialist has recommended the medicine 12 90.4 84.1 1.78 (1.16, 2.72)
Doctor other than your regular doctor has suggested 23 63.9 59.5 1.21 (0.91, 1.60)
Cost
That you can afford the medicine 13 87.7 83.9 1.37 (0.92, 2.04)
How long you will need to buy the medicine 19 77.6 70.8 1.43 (1.04, 1.96)
How much the medicine will cost 20 74.4 72.4 1.11 (0.81, 1.51)
Burden
How long it will take before the medicine starts to work 16 83.1 75.3 1.62 (1.15, 2.28)
Whether medicine means extra monitoring ⁄ follow-up) 18 82.1 72.8 1.72 (1.23, 2.40)
How long you will need to keep taking the medicine 21 75.1 71.6 1.20 (0.88, 1.64)
How often you will need to take medicine (three times per day) 22 70.3 63.6 1.35 (1.01, 1.81)
Familiarity
Having taken a similar medicine previously 24 60.2 55.0 1.24 (0.93, 1.64)
What you have heard about the medicine in the media 25 43.2 39.6 1.16 (0.88, 1.53)
What family members say about the medicine 26 37.3 29.7 1.41 (1.05, 1.89)
What friends say about the medicine 27 21.0 17.4 1.26 (0.89, 1.79)
*Remains statistically significant after adjustment for age, sex, education, employment status, marital status, private health insurance and self-
reported general health (adjusted OR 2.80, 95% CI 1.31, 5.99).
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reported as an important influence on the deci-
sion to use a medicine; a doctor other than your
regular doctor was ranked lower in importance
(rank 23).
The importance of medicine costs seemed to
be in the context of being able to afford the
medicine (rank 13) i.e. relative to their own cir-
cumstances rather than about how long they
would need to buy the medicine or how much the
medicine will cost (ranks 19 and 20, respectively).
The potential burden associated with taking
the medicine (need for additional monitoring or
follow-up, how long you would need to keep
taking the medicine, and how many times a day)
appeared to be of less concern to the respon-
dents (ranks 18, 21, 22).
The lowest ranked items in this survey related
to familiarity with the medicine through having
had previous experience of it, what participants
had heard about the medicine in the media and
the opinions of family and friends (ranks 24–27).
Family views appeared to be a stronger influence
than those of friends (rated as important or very
important by 33 and 19% of overall respon-
dents, respectively).
Roles in decision making
Active participation in the decision to start a
new medicine was reported as important or very
important to almost 91% of the respondents
(rank 7 in the medicine attributes survey), with
no differences between concession card holders
(90.6%) and general beneficiaries (90.9%).
Results for the Degner Control Preferences
Scale are shown in Table 3. Logistic regression
analysis showed statistically significant differ-
ences between the two groups, with concession
card holders more likely than general beneficia-
ries to allow doctors to have more say in the
decision-making process (crude OR 1.69, 95%
CI 1.28, 2.24). However, after adjustment for
demographic variables, the differences were no
longer statistically significant (adjusted OR 0.89,
95% CI 0.59, 1.34).
Leave the decision to the doctor was the
stated decision-making preference for 14.8% of
concession card holders and 6.4% of general
beneficiaries (Table 3). Yet, when asked to recall
the most recent decision to start a new medicine,
61.2% of concession card holders and 40.3% of
general beneficiaries reported that the doctor
alone had made the decision. While concession
care holders were less likely to make their own
decisions about starting medication (crude OR
0.44, 95%CI 0.33, 0.57), this effect disappeared
after adjustment for demographic variables
(adjusted OR 0.98, 95% CI 0.65, 1.46).
Satisfaction with information provided
Overall, around one-quarter of study partici-
pants reported that no information was pro-
vided on the potential side effects of the last new
medicine prescribed for them; around 13% said
they would have liked more information
(Table 4). Cost was not discussed in around
63% of cases (60% of concession card holders
and almost 70% of general beneficiaries,
Table 4), yet few respondents suggested they
wanted more information on the cost of the
medicine prescribed.
Table 3 Responses on the Degner
Control Preferences Scale
Stated decision-making preference
Number of respondents (%)
Concession card
holders
N = 405 (%)
General
beneficiaries
N = 408 (%)
Make decision yourself 6 (1.5) 15 (3.7)
Yourself after considering doctors opinion 47 (11.6) 74 (18.1)
You and doctor share decision equally 263 (64.9) 252 (61.8)
Your doctor after considering doctors opinion 29 (7.2) 41 (10.0)
Leave decision to doctor 60 (14.8) 26 (6.4)
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Discussion
Overall, there were few differences between the
concession card holders and general beneficiary
respondents in the ratings and rankings of the
medicine attributes examined in this study.
After adjustment for differences in demographic
characteristics, the only statistically significant
difference between the two groups was the
greater influence of the regular doctor on
decision making for concession card holders.
Poorer health, more illness and more contact
with the medical profession along with lower
educational achievement and older age of the
concession card holders might explain these
observations. Lower education will heighten the
information asymmetry between doctor and
patient16, and older age is associated with
more traditional, paternalistic doctor–patient
relationships.16 This study underscores the
importance of multivariate adjustment when
evaluating the impacts of different levels of
insurance subsidy. It does not appear from
these data that the different levels of subsidy
that exist in the Australian Pharmaceutical
Benefits Scheme are associated with major dif-
ferences in attitudes or behaviours in respect of
prescription medicines.
There is increasing evidence that patient co-
payments, a feature of the Australian Pharma-
ceutical Benefits Scheme, cause financial con-
cern2,17 and may influence prescription
acquisition and use for some Australians.3–5,18
Given the higher co-payments of the general
beneficiary group (AU$ 31.30 per item at the
time of the survey), it might have been expected
that cost was of greater importance to this
group. However, cost was mostly not discussed
during consultations, and for all three cost
questions, higher proportions of concession card
holders reported it to be an important consid-
eration. Cost appears to be an affordability
issue, the co-payment for concession card hold-
ers (AU$ 5.00 at the time of the survey) might be
a relatively greater impost on a household bud-
get reliant on a pension or other social security
support. However, there is separate evidence
that medicine costs are a particular problem for
the working poor,2 i.e. those with low house-
hold income, with one or more members with
chronic disease, who are not eligible to purchase
prescriptions at the concessional rate. There
were too few participants in this category to
examine this further in this study.
Significantly, for both groups, medicine use
was studied in the context of an established
Table 4 Satisfaction with information
provided on benefits, side effects and











Received none 44 (11.1) 22 (5.4) 0.84 (0.53, 1.32)
Wanted more 44 (11.1) 60 (14.8)
As much as I wanted 290 (73.2) 298 (73.4)
More than I wanted 18 (4.5) 26 (6.4)
Side effects
Received none 114 (28.4) 85 (21.1) 0.85 (0.57, 1.27)
Wanted more 46 (11.5) 64 (15.9)
As much as I wanted 225 (56.1) 227 (56.5)
More than I wanted 16 (4.0) 26 (6.5)
Cost
Received none 235 (59.9) 280 (69.3) 1.66 (1.08, 2.56)
Wanted more 5 (1.3) 12 (3.0)
As much as I wanted 148 (37.8) 105 (26.2)
More than I wanted 4 (1.0) 6 (1.5)
*Adjusted for age, gender, education, employment status, marital status, having their own GP
and in a health fund.
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need, based on the advice of the general practi-
tioner. The regular doctor or specialist was
particularly important as trusted decision maker
for the patient. The influence of the doctor was
not surprising; 95% of respondents reported
having a regular GP, and all respondents were
regular prescription medicine users. Most will
have established relationships with their doctors
that involve a high level of trust and acceptance
of the doctors advice. After need, issues of
benefit and risk were rated as the most impor-
tant considerations. It seems that once the
decision has been made that the medicine is
needed and that the potential benefits outweigh
the perceived risks, other considerations,
including copayments, are of lesser importance.
There were no differences between the two
groups on the single question exploring decision-
making preference, with 91% of each group
reporting participation in decision making as
important or very important. However,
responses on the validated Control Preferences
Scale suggest that concession card holders were
more likely to describe themselves as leaving the
decision to the doctor (15 vs. 6%), although the
difference was not statistically significant after
adjustment for demographic variables. The
stated preferences for decision making were
substantially different to recall for the most
recent decision to start a medicine where 61% of
concession card holders and 40% of general
beneficiaries reported that the doctor alone
made the decision. We did not assess satisfaction
with the decision-making process.
This apparent dissonance between stated and
revealed preferences might be explained in part
by personal perception and descriptions of
decision making. While both groups agreed that
involvement in decision making was important,
what may differ is how this plays out and is
interpreted in the clinical context. The desire for
information is not the same as desire to partic-
ipate in decision making;19 patients may want to
be informed and actively discuss treatment
options but prefer decisions to be made princi-
pally by the physician.20,21 Others have made the
distinction between the process of involvement
(option portrayal, exchange of information and
exploring preferences for who makes the deci-
sion and when) and the actual decisional
responsibility (who makes the decision).22 In an
interview study, Smith et al.23 found that those
with higher levels of education tended to see
themselves as sharing responsibility with the
doctor throughout the decision-making process.
Those with lower education tended to view their
role as consenting to an option recommended by
the doctor, accepting responsibility for decision
making by agreeing or disagreeing with the
recommendation.
The factors or components we identified as
influencing decision making for prescription
medicines are similar to those included with
other descriptions and scales assessing satisfac-
tion with medicines.9–11,24 Shikiar and Rentz8
have suggested that under some circumstances
patients might be willing to trade-off medicine
features, for example favouring a medicine that
is quicker acting but with a less favourable side
effect profile, or a more convenient dosage
schedule when benefits and risks are similar.
The results of our study do not allow us to
comment on this directly. We have identified
and ranked medicine attributes according to
their reported importance to patients. Willing-
ness or ability to trade on these dimensions is
likely to be influenced by many things. If the
illness is severe or life threatening, a high risk of
side effects alongside a small chance of benefit
might be entirely reasonable and at whatever
cost. For less severe, chronic conditions, per-
sistent side effects may be intolerable and may
make the patient stop therapy altogether. In
other cases, it may be an issue of cost, where
the patient may not be able to afford the more
effective, more convenient medicine regardless
of the established need and the recommenda-
tion of the doctor. It is possible that while
patients report the importance of medicine
attributes to their decisions, in practice, they
rely on their doctors to interpret differences in
these attributes and delegate authority to the
doctor to make the decision for them. This
interpretation is most consistent with the
reports of the most recent prescribing decision
in this study.
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This study has a number of limitations. It was
conducted in a single region – the Hunter region
of New South Wales. However, while there are
some demographic differences between the
Hunter and other Australian regions, there is no
reason to expect responses to be substantially
different elsewhere in Australia. We focused
predominantly on pharmacological approaches
to disease management, asking patients to
imagine a clinical condition and a new medicine
for its treatment. While differences in the sever-
ity of a clinical condition envisaged and the
consequences of not treating it may have influ-
enced the importance ratings assigned by par-
ticipants, the domains identified as important
are consistent with other studies exploring sat-
isfaction with medicines. For 15 of the 27 items,
more than 80% of respondents considered it
important or very important to have informa-
tion on that aspect of the medicine making it
difficult to identify meaningful differences on
some components. However, the ratings for the
attributes of cost, burden and familiarity were
substantially lower than the ratings for need,
benefits and risks.
Conclusion
This study showed that concession card holders
and general beneficiary respondents generally
agreed on the importance of the attributes of
medicines that influence their decisions about
taking a new medicine. The main difference was
the greater influence of the regular doctor on
decision making for concession card holders.
The dominant issue is establishing the need for
the medicine, followed by a consideration of the
benefits and risks associated with it. Issues of
cost, burden and experience or familiarity with
the medicine were ranked as less important.
More than 90% of respondents thought it
important to be directly involved in the decision
about a new medicine, yet around 50% reported
that the most recent decision to start a new
medicine was made by the doctor alone. Dele-
gation of decision-making authority to the doc-
tor may be the logical response to the complexity
of evaluating different medicine attributes. In
the Australian health insurance system, the level
of subsidy appears to play no important role in
determining views about medicines or decision-
making preferences.
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